Overall response according to baseline patient features
| Feature . | No. of patients . | No. of patients with response . | % . |
|---|---|---|---|
| Total group | 28 | 7 | 25 |
| No. of previous treatments | |||
| ≤ 3 | 17 | 5 | 29 |
| > 3 | 11 | 2 | 18 |
| Binet stage | |||
| B | 11 | 3 | 27 |
| C | 17 | 4 | 24 |
| B symptoms | |||
| Yes | 13 | 5 | 38 |
| No | 15 | 2 | 13 |
| Bone marrow infiltration pattern (n = 26) | |||
| Nodular | 13 | 4 | 31 |
| Diffuse/mixed | 13 | 2 | 15 |
| Lymphocyte count | |||
| Normal | 11 | 3 | 27 |
| Pathological | 17 | 4 | 24 |
| Karnofsky index | |||
| ≤ 80% | 13 | 2 | 15 |
| 90%-100% | 15 | 5 | 33 |
| LDH (n = 26) | |||
| < 250 U/L | 14 | 4 | 29 |
| ≥ 250 U/L | 12 | 1 | 8 |
| β2-microglobulin (n = 22) | |||
| < 425.0 nM/L | 14 | 5 | 36 |
| ≥ 425.0 nM/L | 8 | 2 | 25 |
| CD20 expression3-150 | |||
| < 10 (very dim) | 5 | 2 | 40 |
| 10-40 (dim) | 18 | 5 | 28 |
| > 40 (bright) | 4 | 0 | 0 |
| Feature . | No. of patients . | No. of patients with response . | % . |
|---|---|---|---|
| Total group | 28 | 7 | 25 |
| No. of previous treatments | |||
| ≤ 3 | 17 | 5 | 29 |
| > 3 | 11 | 2 | 18 |
| Binet stage | |||
| B | 11 | 3 | 27 |
| C | 17 | 4 | 24 |
| B symptoms | |||
| Yes | 13 | 5 | 38 |
| No | 15 | 2 | 13 |
| Bone marrow infiltration pattern (n = 26) | |||
| Nodular | 13 | 4 | 31 |
| Diffuse/mixed | 13 | 2 | 15 |
| Lymphocyte count | |||
| Normal | 11 | 3 | 27 |
| Pathological | 17 | 4 | 24 |
| Karnofsky index | |||
| ≤ 80% | 13 | 2 | 15 |
| 90%-100% | 15 | 5 | 33 |
| LDH (n = 26) | |||
| < 250 U/L | 14 | 4 | 29 |
| ≥ 250 U/L | 12 | 1 | 8 |
| β2-microglobulin (n = 22) | |||
| < 425.0 nM/L | 14 | 5 | 36 |
| ≥ 425.0 nM/L | 8 | 2 | 25 |
| CD20 expression3-150 | |||
| < 10 (very dim) | 5 | 2 | 40 |
| 10-40 (dim) | 18 | 5 | 28 |
| > 40 (bright) | 4 | 0 | 0 |
CD20 expression of CLL cells quantified as the ratio of fluorescence mean channels of CD20+ versus CD20− cells.